The National Health Service is embarking on a groundbreaking clinical trial of a novel device known as the "Zeus Sleep device," which holds significant promise for the estimated eight million individuals across the United Kingdom who suffer from sleep apnoea. This chronic sleep disorder is characterised by repeated interruptions in breathing during sleep, leading to symptoms such as severe fatigue, impaired concentration, and heightened risks of cardiovascular diseases like heart disease.
Innovative alternative to traditional treatments
Unlike the current gold-standard treatment, Continuous Positive Airway Pressure (CPAP) machines, which many patients find cumbersome and uncomfortable, the Zeus Sleep device offers a more user-friendly approach. It is designed to be worn discreetly under the chin and utilises gentle electrical stimulation to prevent the collapse of the airway during sleep, thereby maintaining normal breathing patterns.
Expert-led trial across NHS regions
The trial will be spearheaded by experts from Guy’s and St Thomas’ NHS Foundation Trust in collaboration with King’s College London. Starting this summer, the study aims to recruit approximately 200 patients from seven different NHS areas, ensuring a diverse and representative sample to assess the device's effectiveness and safety in real-world settings.
Promising results from previous studies
Early research and previous studies on similar devices have yielded encouraging outcomes. For instance, data indicates that 84 per cent of users reported improved sleep quality, while 85 per cent continued using the device long-term. These compliance rates are notably higher than those associated with CPAP machines, suggesting that the Zeus Sleep device could address common barriers to treatment adherence among sleep apnoea patients.
This trial represents a crucial step forward in sleep medicine, potentially transforming the management of a debilitating condition that affects millions. If successful, the device could offer a more comfortable and effective solution, enhancing the quality of life for sufferers and reducing the long-term health risks linked to untreated sleep apnoea.
